Aytu biopharma announces positive preclinical data in ventilator-associated pneumonia with its novel, proprietary healight(tm) delivery technology

Preclinical proof-of-concept study demonstrates effectiveness of healight in delaying time to development of ventilator-associated pneumonia englewood, co / accesswire / april 25, 2022 / aytu biopharma, inc. (nasdaq:aytu), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced positive results from a preclinical pilot study showing that administration of its healight™ ultraviolet light a (uva) endotracheal catheter delayed the time to development of ventilator-associated pneumonia (vap) in a novel porcine model. healight is the company's patented, investigational medical device technology employing proprietary methods of administering intermittent uva light delivered via a novel respiratory endotracheal catheter.
AYTU Ratings Summary
AYTU Quant Ranking